Matrix IntraDose “not approvable”
Executive Summary
Matrix' IntraDose (cisplatin/epinephrine injectable gel) receives "not approvable" letter from FDA Nov. 2. The letter reiterates agency concerns raised at the Sept. 10 advisory committee meeting for the head and neck cancer agent, Matrix says (1"The Pink Sheet" Sept. 24, p. 30). The company is "continuing to explore with the FDA the next steps for IntraDose." Phase II trials for other cancer indications will not proceed to Phase III, Matrix says...
You may also be interested in...
Cancer Clinical Benefit Tool Needed For Local Therapies -IntraDose Cmte
An effective tool needs to be developed to assess the clinical benefit of local cancer therapies, FDA's Oncologic Drugs Advisory Committee concluded Sept. 10 in voting down Matrix' IntraDose.
Cosmetic And Personal Care Trademark Review: 16 April
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
Health And Wellness Weekly Trademarks Review: 16 April
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.